– USA, PA – Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Dr. Sarah Noonberg (M.D., Ph.D.) to its Board of Directors.
About Dr. Sarah Noonberg
Dr. Noonberg is a physician-scientist with a diverse background in translational science, clinical development, medical affairs, and corporate governance. She has significant experience designing and leading rare disease programs from discovery to global regulatory approvals and commercialization. Dr. Noonberg currently serves as CMO of Metagenomi, a privately held genomics company, where she is advancing its gene editing technology platform toward the clinic. She previously served as CMO of Maze Therapeutics, Nohla Therapeutics, and Prothena Biosciences and before that, held clinical development executive leadership roles at BioMarin and Medivation. Her industry experience is complemented by more than 10 years of experience treating patients as a hospitalist physician.
Dr. Noonberg currently serves on the Board of Directors at Protagonist Therapeutics and Neoleukin Therapeutics. She trained in internal medicine at Johns Hopkins Hospital, received an M.D. from the University of California, San Francisco, a Ph.D. in bioengineering from the University of California, Berkeley, and a bachelor’s degree in engineering science from Dartmouth College.
About Marinus Pharmaceuticals
Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s commercial product, ZTALMY (ganaxolone) oral suspension CV, has been approved by the U.S. FDA for the treatment of seizures associated with CDKL5 deficiency disorder in patients two years of age and older. The potential of ganaxolone is also being studied in other rare seizure disorders, including in Phase 3 trials in tuberous sclerosis complex and refractory status epilepticus. Ganaxolone is a neuroactive steroid GABAA receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. It is being developed in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.